blonanserin has been researched along with piperidines in 99 studies
| Studies (blonanserin) | Trials (blonanserin) | Recent Studies (post-2010) (blonanserin) | Studies (piperidines) | Trials (piperidines) | Recent Studies (post-2010) (piperidines) |
|---|---|---|---|---|---|
| 121 | 21 | 93 | 40,235 | 5,221 | 14,545 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (4.04) | 18.2507 |
| 2000's | 8 (8.08) | 29.6817 |
| 2010's | 64 (64.65) | 24.3611 |
| 2020's | 23 (23.23) | 2.80 |
| Authors | Studies |
|---|---|
| Furukawa, K; Hino, K; Karasawa, T; Kurumiya, S; Noda, Y; Ochi, Y; Oka, M; Une, T | 1 |
| Kurumiya, S; Miura, Y; Noda, Y; Oka, M | 1 |
| Fujii, T; Matsuda, M; Sakashita, M; Yamaguchi, T | 1 |
| Fukuda, A; Matsuno, T; Matsuo, T; Motomura, H; Shoge, T; Tashiro, N; Tatebayashi, H; Yokota, K | 1 |
| Fujiwara, I; Hiyama, Y; Suzuki, K; Une, T | 1 |
| Furukawa, H; Furukawa, K; Kan, QM; Nabeshima, T; Nagai, T; Noda, Y; Une, T | 1 |
| Matsumoto, K; Minamida, A; Ochi, T; Sakamoto, M; Suzuki, K; Terauchi, Y; Toda, H; Ueda, T; Une, T | 1 |
| Ishibashi, T; Nakamura, H; Nishikawa, H; Une, T | 1 |
| Garcia, E; Nakamura, H; Peris, F; Robert, M; Sato, N; Terazawa, Y | 1 |
| Ichimiya, Y; Kumagai, R | 1 |
| Deeks, ED; Keating, GM | 1 |
| Imaki, J; Ohno, Y; Okano, M; Okumura, T; Shimizu, S; Tatara, A | 1 |
| Inoue, Y; Kaneko, S; Saruwatari, J; Yasui-Furukori, N | 1 |
| Ishitobi, M; Kosaka, H; Murata, T; Shukunami, K; Wada, Y | 1 |
| Bahk, WM; Cho, HS; Jeon, YW; Jon, DI; Jung, HY; Kim, CH; Kim, HC; Kim, SH; Kim, YH; Kim, YK; Kwon, JS; Lee, SH; Lee, SY; Yang, J; Yi, JS; Yoon, BH | 1 |
| Akama, F; Andoh, H; Kato, K; Matsumoto, H; Sakaguchi, T; Sato, R | 1 |
| Arinobu, T; Hattori, H; Ishii, A; Ito, K; Iwai, M; Kaneko, R; Mizutani, Y; Ogawa, T; Seno, H; Suzuki, O | 1 |
| Hamaguchi, T; Motomura, E; Nakagawa, M; Ohoyama, K; Okada, M; Shiroyama, T; Tanii, H; Yamamura, S | 1 |
| Hamuro, A; Saito, S | 1 |
| Konishi, Y; Matsumoto, T; Motomura, E; Nakagawa, M; Ohoyama, K; Okada, M; Shiroyama, T; Tanii, H | 1 |
| Kato, M; Kinoshita, T; Nishida, K; Sakai, S; Suwa, A; Tajika, A; Takekita, Y; Yoshimura, M | 1 |
| Akama, F; Ichimura, A; Kato, K; Kimoto, K; Maehara, M; Matsumoto, H; Saito, M; Yamada, K; Yano, H | 1 |
| Kurotaki, N; Nishihara, K; Nobata, H; Nonaka, S; Ozawa, H | 1 |
| Anai, K; Arai, J; Funamoto, Y; Ito, Y; Kaneda, Y; Kitajima, R; Miyake, N; Miyamoto, S; Ogino, S; Ojima, K; Sumiyoshi, T; Tadokoro, M; Tenjin, T; Teramoto, H; Tsukahara, S; Yamaguchi, N | 1 |
| Gen, K; Suzuki, H | 1 |
| Liu, J; Lu, D; Peng, M; Yang, YJ | 1 |
| Fukui, N; Ono, S; Saito, M; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J | 2 |
| Haga, T; Hashizume, T; Inoue, T; Katsumata, T; Ogawa, Y; Osada, K; Sogame, Y; Tagawa, M; Taguchi, A; Watanabe, T; Yabuki, M; Yamaguchi, N | 1 |
| Liu, X; Ni, XJ; Shang, DW; Wen, YG; Zhang, M | 1 |
| Iwata, N; Kishi, T; Matsuda, Y; Nakamura, H | 1 |
| Li, FF; Li, X; Liu, X; Lu, W; Luo, FT; Ni, XJ; Qiu, C; Shang, DW; Wang, XP; Wen, YG; Xie, HZ; Zhang, M | 1 |
| Arakawa, R; Fukuta, H; Honjo, K; Ishihara, K; Kumita, S; Nakamura, H; Okubo, Y; Okumura, M; Tateno, A | 1 |
| Akama, F; Kato, K; Kimoto, K; Maehara, M; Matsumoto, H; Sato, R; Takahashi, Y; Yamada, K | 1 |
| Horiguchi, M; Meltzer, HY | 1 |
| Amrutheshwar, R; Dkhar, SA; George, M; Kattimani, S; Rajkumar, RP | 1 |
| Miyamoto, S; Tenjin, T | 1 |
| Abe, H; Ebihara, K; Funahashi, H; Ikeda, T; Ishida, Y; Koganemaru, G; Kuramashi, A; Matsuo, H; Nishimori, T; Takeda, R | 1 |
| Suzuki, M; Takahashi, S; Uchiyama, M | 1 |
| Hasegawa, T; Hibi, S; Kito, S; Koga, Y; Mochida, M; Nakajima, T; Tobe, Y | 1 |
| Hu, P; Jiang, J; Liu, M; Wang, H; Zhou, Y | 1 |
| Huang, M; Kwon, S; Meltzer, HY; Oyamada, Y; Panos, JJ; Rajagopal, L | 1 |
| Bhatia, MS; Jhanjee, A; Rathi, A | 1 |
| Chen, R; Chen, X; Hu, P; Jiang, J; Liu, H; Wang, H; Zhong, W; Zhou, Y | 1 |
| Bundo, M; Iwamoto, K; Kasai, K; Murata, Y; Nishioka, M; Sunaga, F | 1 |
| Iwata, N; Kishi, T; Matsuda, Y | 2 |
| Kanno-Nozaki, K; Katsumi, A; Mashiko, H; Miura, I; Niwa, S; Shiga, T; Yabe, H | 1 |
| Miki, T; Mizuki, Y; Takaki, M | 1 |
| Kaneda, Y; Miyake, N; Miyamoto, S; Ninomiya, Y; Ogino, S; Sumiyoshi, T; Tenjin, T; Yamaguchi, N | 1 |
| Fukui, K; Fukushima, T; Hakariya, H; Ichiba, H; Iwasa, S; Shishikura, M; Yorita, K; Yoshio, T | 1 |
| Bavle, A | 1 |
| Hida, H; Iwamoto, K; Matsumoto, Y; Mori, K; Mouri, A; Nabeshima, T; Noda, Y; Ozaki, N; Seki, T; Taniguchi, M; Yamada, K | 1 |
| Mizuki, Y; Takaki, M | 1 |
| Baba, S; Enomoto, T; Ikeda, K; Murai, T; Nakako, T; Ono, M; Shimizu, I | 1 |
| Baba, S; Enomoto, T; Hashimoto, T; Horisawa, T; Ono, M | 1 |
| Gu, N; Li, H; Li, J; Li, K; Li, L; Liu, C; Luo, X; Qi, S; Shi, J; Wang, C; Wang, L; Wang, Q; Yang, F; Yao, C; Zhang, H | 1 |
| Masui, A; Minamimoto, S; Mizobe, Y; Mizuguchi, Y; Ochiai, M; Ohno, Y; Shimizu, S; Tamura, M; Tatara, A | 1 |
| Huang, M; Kwon, S; Meltzer, HY; Miyauchi, M; Oyamada, Y; Rajagopal, L | 1 |
| Enomoto, T; Ikeda, K; Ikejiri, M; Iwamura, Y; Kiyoshi, A; Kotani, M; Matsumoto, A; Matsumoto, K; Murai, T; Nakako, T; Nakayama, T; Ogi, Y | 1 |
| Gopalakrishna, G; Ithman, MH; Lauriello, J | 1 |
| Hashimoto, T; Ishikawa, M; Iyo, M; Kanahara, N; Niitsu, T; Tachibana, M; Watanabe, M | 1 |
| Arima, H; Hamada, Y; Nakao, M; Noda, Y; Oiso, Y; Tsubai, T; Yoshimi, A | 1 |
| Li, L; Liao, M; Liu, B; Xu, S; Zhang, Y; Zheng, Q | 1 |
| Hu, HT; Hu, JQ; Lu, HY; Ni, XJ; Peng, H; Qiu, C; Shang, DW; Shen, LF; Wang, ZZ; Wen, YG; Zhang, M; Zhang, YF | 1 |
| Hashimoto, N; Kuksumi, I; Miyamoto, T; Miyazaki, A; Toyomaki, A | 1 |
| Arakawa, R; Honjo, K; Kim, WC; Nakayama, H; Okubo, Y; Sakayori, T; Tateno, A | 1 |
| Chen, Y; Deng, S; Hu, J; Lu, H; Ni, X; Peng, H; Shang, D; Wang, Z; Wen, Y; Zhang, M; Zhang, Y; Zhu, X | 1 |
| Hagi, K; Hori, H; Iwata, N; Katsuki, A; Kishi, T; Matsuda, Y; Matsui, Y; Morita, K; Sanada, K; Shoji, Y; Yanagimoto, H; Yoshimura, R | 1 |
| Cuyckens, F; Dening, TJ; Holm, R; Prestidge, CA; Rao, S; Thomas, N; van Looveren, C | 1 |
| Deriha, K; Furuse, K; Hashiguchi, H; Hashimoto, E; Ishii, T; Kawanishi, C; Kigawa, Y; Shiraishi, M; Tayama, M; Ukai, W | 1 |
| Harvey, PD; Murasaki, M; Nakamura, H | 1 |
| Agarkov, A; Correll, CU; Cosca, R; Higuchi, T; Inoue, Y; Ishigooka, J; Iwata, N; Kane, JM; Kim, WH; Lin, SK; Matsui, T; Sato, T; Suchkov, Y; Sulaiman, AH; Wang, L; Watabe, K; Yoon, BH | 1 |
| Horiuchi, F; Kawabe, K; Ueno, SI | 1 |
| Chiba, K; Goto, A; Hagiwara-Nagasawa, M; Izumi-Nakaseko, H; Kambayashi, R; Matsumoto, A; Naito, AT; Sugiyama, A | 1 |
| Andrade, C; Harshe, D; Tekkalaki, B; Tharayil, HM | 1 |
| Nishitani, N; Ohmura, Y; Sasamori, H; Yoshida, T; Yoshioka, M | 1 |
| Harvey, PD; Miura, S; Nakamura, H | 1 |
| Lei, L; Li, H; Li, Y; Shen, Y; Yu, W; Yu, Y | 1 |
| Higuchi, T; Ishigooka, J; Iwata, N; Kanamori, Y; Matsumoto, M; Nakamura, H; Naoi, I | 1 |
| Iwata, N; Kishi, T; Matsuda, Y; Sakuma, K; Yoshimura, R | 1 |
| Begni, V; Brivio, P; Calabrese, F; Guidi, A; Marchisella, F; Molteni, R; Paladini, MS; Riva, MA; Spero, V | 1 |
| Endo, M; Fujita, K; Fukami, G; Hashimoto, T; Hata, T; Hattori, N; Hosoda, Y; Imamura, Y; Inoue, M; Ishikawa, M; Iyo, M; Kanahara, N; Kawasaki, Y; Kimura, A; Murakami, T; Niitsu, T; Nishimoto, M; Oda, Y; Ogawa, K; Sato, T; Seki, R; Shiina, A; Suzuki, M; Takase, N; Yoshida, T | 1 |
| Kakuyama, H; Kim, W; Nishibe, H; Okubo, Y; Sakayori, T; Tateno, A; Yamamoto, M | 1 |
| Meola, TR; Müllertz, A; Møller, A; Prestidge, CA; Schultz, HB | 1 |
| Begni, V; Gruca, P; Guidi, A; Lason, M; Litwa, E; Marchisella, F; Molteni, R; Paladini, MS; Papp, M; Riva, MA; Spero, V | 1 |
| Akiyama, Y; Arihara, M; Kimura, Y; Komatsu, K; Mikami, T; Mikuni, N; Sakashita, K | 1 |
| Inoue, Y; Nakamura, H; Tsuchimori, K | 1 |
| Imamura, A; Kanegae, S; Matsuzaka, Y; Morimoto, Y; Nakano, T; Ozawa, H; Sakai, S | 1 |
| Fujita, K; Iga, JI; Inada, K; Ishigooka, J; Iwata, N; Kanda, Y; Kikuchi, Y; Kishi, T; Kishimoto, T; Koretsune, S; Nakagome, K; Ohi, K; Ohmori, T; Sekiyama, K; Shichijo, T; Tabuse, H; Terada, H; Tsutsumi, Y | 1 |
| Hashimoto, N; Ishikawa, S; Ito, YM; Kusumi, I; Okubo, R; Sato, N; Sawagashira, R; Yamamura, R | 1 |
| Kuramitsu, A; Ohi, K; Shioiri, T; Sugiyama, S; Takai, K | 1 |
| Nakamura, T; Sasayama, D; Takahashi, K; Washizuka, S; Yokotsuka-Ishida, S | 1 |
| Hu, Y; Wen, H; Zheng, Y | 1 |
| Iwata, N; Kishi, T; Matsuura, A; Nakamura, H | 1 |
| Bo, Q; Deng, H; Hu, S; Inoue, Y; Lei, L; Liu, Z; Pu, C; Sheng, J; Wang, L; Wu, B; Yang, F; Yu, X | 1 |
| Nakao, S; Ohmori, S; Okamoto, K; Shimizu, T; Tsuchiya, N | 1 |
11 review(s) available for blonanserin and piperidines
| Article | Year |
|---|---|
[Pharmacological profiles and clinical effects of blonanserin (Lonasen) on schizophrenia].
Topics: Animals; Antidepressive Agents, Second-Generation; Cognition Disorders; Dopamine D2 Receptor Antagonists; Double-Blind Method; Drug Discovery; Drug-Related Side Effects and Adverse Reactions; Humans; Piperazines; Piperidines; Randomized Controlled Trials as Topic; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome | 2008 |
Blonanserin: a review of its use in the management of schizophrenia.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Drug Interactions; Humans; Piperazines; Piperidines; Schizophrenia; Schizophrenic Psychology | 2010 |
Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials.
Topics: Antiparkinson Agents; Double-Blind Method; Humans; Piperazines; Piperidines; Psychiatric Status Rating Scales; PubMed; Randomized Controlled Trials as Topic; Schizophrenia; Treatment Outcome | 2013 |
Newer antipsychotics and upcoming molecules for schizophrenia.
Topics: Antipsychotic Agents; Dibenzocycloheptenes; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lurasidone Hydrochloride; Piperazines; Piperidines; Schizophrenia; Thiazoles | 2013 |
[Blonanserin in the treatment of schizophrenia].
Topics: Antipsychotic Agents; Cognition; Humans; Japan; Piperazines; Piperidines; Quality of Life; Schizophrenia; Treatment Outcome | 2013 |
Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Double-Blind Method; Glycated Hemoglobin; Heart; Humans; Isoindoles; Piperazines; Piperidines; Randomized Controlled Trials as Topic; Risk; Schizophrenia; Thiazoles; Weight Gain | 2014 |
Update on New and Emerging Treatments for Schizophrenia.
Topics: Antipsychotic Agents; Drug Approval; Excitatory Amino Acid Agents; Glycine Agents; Humans; Minocycline; Nicotinic Agonists; Phosphodiesterase Inhibitors; Piperazines; Piperidines; Schizophrenia | 2016 |
[Research progress in mechanisms and clinical application for blonanserin and lurasidone in improving cognitive function of schizophrenia].
Topics: Antipsychotic Agents; Cognition Disorders; Humans; Lurasidone Hydrochloride; Piperazines; Piperidines; Schizophrenia; Schizophrenic Psychology | 2017 |
Efficacy, Tolerability, and Safety of Blonanserin in Schizophrenia: An Updated and Extended Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Antipsychotic Agents; Humans; Piperazines; Piperidines; Randomized Controlled Trials as Topic; Schizophrenia | 2019 |
Blonanserin patch vs. Other Antipsychotics for Acute Schizophrenia: A Systematic Review of Double-blind, Randomized, Placebo-controlled, Phase 3 Trials in Japan.
Topics: Acute Disease; Administration, Cutaneous; Antipsychotic Agents; Clinical Trials, Phase III as Topic; Double-Blind Method; Humans; Japan; Piperazines; Piperidines; Randomized Controlled Trials as Topic; Schizophrenia | 2020 |
Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Child; Female; Humans; Japan; Male; Middle Aged; Piperazines; Piperidines; Product Surveillance, Postmarketing; Safety; Schizophrenia; Treatment Outcome; Young Adult | 2021 |
21 trial(s) available for blonanserin and piperidines
| Article | Year |
|---|---|
The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Haloperidol; Humans; International Cooperation; Male; Middle Aged; Piperazines; Piperidines; Prospective Studies; Psychiatric Status Rating Scales; Schizophrenia; Severity of Illness Index; Young Adult | 2009 |
Effect of dose timing in relation to food intake on systemic exposure to blonanserin.
Topics: Administration, Oral; Adult; Area Under Curve; Asian People; Biological Availability; Confounding Factors, Epidemiologic; Cross-Over Studies; Drug Administration Schedule; Eating; Fasting; Female; Food-Drug Interactions; Humans; Male; Piperazines; Piperidines; Postprandial Period; Reference Values; Research Design; Time Factors | 2010 |
Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hyperprolactinemia; Male; Middle Aged; Piperazines; Piperidines; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Weight Gain; Young Adult | 2010 |
Five Alzheimer's disease cases with refractory behavioural psychological symptoms of dementia treated with blonanserin.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Basal Ganglia Diseases; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Humans; Japan; Male; Mental Disorders; Mental Status Schedule; Neuropsychological Tests; Piperazines; Piperidines; Prospective Studies; Psychometrics; Receptor, Serotonin, 5-HT2A; Treatment Outcome | 2010 |
Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Chronic Disease; Cognition Disorders; Female; Humans; Male; Piperazines; Piperidines; Prospective Studies; Psychiatric Status Rating Scales; Quality of Life; Schizophrenia; Severity of Illness Index; Single-Blind Method; Treatment Outcome; Young Adult | 2012 |
Simultaneous determination of blonanserin and its metabolite in human plasma and urine by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study.
Topics: Adolescent; Adult; Chromatography, High Pressure Liquid; Drug Stability; Female; Humans; Male; Piperazines; Piperidines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2012 |
Population pharmacokinetics of blonanserin in Chinese healthy volunteers and the effect of the food intake.
Topics: Administration, Oral; Adolescent; Adult; Asian People; Eating; Female; Food-Drug Interactions; Humans; Male; Piperazines; Piperidines; Young Adult | 2013 |
One-year follow-up study of psychotic patients treated with blonanserin: a case series.
Topics: Adult; Antipsychotic Agents; Female; Follow-Up Studies; Humans; Piperazines; Piperidines; Prolactin; Psychotic Disorders; Quality of Life; Schizophrenia | 2013 |
Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Female; Homovanillic Acid; Humans; Japan; Male; Methoxyhydroxyphenylglycol; Middle Aged; Piperazines; Piperidines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Time Factors; Treatment Outcome | 2014 |
Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Asian People; China; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Piperidines; Prolactin; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Weight Gain; Young Adult | 2015 |
Effects of Alcohol on the Pharmacokinetics of Blonanserin and N-Deethylated Blonanserin in Healthy Chinese Subjects.
Topics: Adult; Antipsychotic Agents; Central Nervous System Depressants; China; Cross-Over Studies; Drug Interactions; Ethanol; Fasting; Humans; Male; Piperazines; Piperidines; Young Adult | 2018 |
Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8-week, double-blind, multicenter, randomized controlled study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Tolerance; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Piperidines; Schizophrenia; Weight Gain | 2019 |
Efficacy and safety of blonanserin transdermal patch in patients with schizophrenia: A 6-week randomized, double-blind, placebo-controlled, multicenter study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Piperidines; Psychiatric Status Rating Scales; Schizophrenia; Transdermal Patch | 2020 |
Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Japan; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Piperidines; Risperidone; Schizophrenia | 2020 |
Model-based analysis of therapeutic efficacy of blonanserin and risperidone in schizophrenia patients and effects on prolactin: A randomized double-blind study.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Models, Statistical; Piperazines; Piperidines; Prolactin; Risperidone; Schizophrenia; Sex Factors; Young Adult | 2020 |
Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study.
Topics: Administration, Cutaneous; Adult; Aged, 80 and over; Asian People; Female; Humans; Male; Middle Aged; Piperazines; Piperidines; Schizophrenia; Transdermal Patch; Treatment Outcome | 2020 |
A randomized-controlled trial of blonanserin and olanzapine as adjunct to antipsychotics in the treatment of patients with schizophrenia and dopamine supersensitivity psychosis: The ROADS study.
Topics: Antipsychotic Agents; Benzodiazepines; Dopamine; Humans; Olanzapine; Piperazines; Piperidines; Psychiatric Status Rating Scales; Psychotic Disorders; Schizophrenia; Treatment Outcome | 2020 |
Striatal Dopamine D2 Receptor Occupancy Induced by Daily Application of Blonanserin Transdermal Patches: Phase II Study in Japanese Patients With Schizophrenia.
Topics: Adult; Antipsychotic Agents; Corpus Striatum; Female; Humans; Japan; Male; Middle Aged; Piperazines; Piperidines; Positron-Emission Tomography; Raclopride; Receptors, Dopamine D2; Schizophrenia; Transdermal Patch; Young Adult | 2021 |
Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second-generation antipsychotics: 52-week evaluation of JUMPs, a randomized, open-label study.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Japan; Male; Medication Adherence; Middle Aged; Paliperidone Palmitate; Piperazines; Piperidines; Remission Induction; Schizophrenia; Social Interaction; Treatment Outcome | 2022 |
Switching from blonanserin oral tablets/powders to transdermal patches alleviates extrapyramidal symptoms in patients with schizophrenia: A 52-week open-label study.
Topics: Administration, Oral; Adult; Antiparkinson Agents; Antipsychotic Agents; Dose-Response Relationship, Drug; Dyskinesias; Female; Humans; Male; Piperazines; Piperidines; Powders; Schizophrenia; Tablets; Transdermal Patch | 2022 |
Effectiveness and safety of blonanserin for improving social and cognitive functions in patients with first-episode schizophrenia: a study protocol for a prospective, multicentre, single-arm clinical trial.
Topics: Antipsychotic Agents; Cognition; Humans; Multicenter Studies as Topic; Piperazines; Piperidines; Prospective Studies; Schizophrenia; Schizophrenic Psychology; Social Interaction; Treatment Outcome | 2022 |
67 other study(ies) available for blonanserin and piperidines
| Article | Year |
|---|---|
Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Biogenic Monoamines; Clozapine; Dogs; Dopamine D2 Receptor Antagonists; Guinea Pigs; Haloperidol; Macaca fascicularis; Male; Mice; Mice, Inbred Strains; Neurotransmitter Uptake Inhibitors; Piperazines; Piperidines; Prosencephalon; Radioligand Assay; Rats; Rats, Wistar; Receptors, Adrenergic, alpha; Receptors, Dopamine D2; Receptors, Serotonin; Serotonin Antagonists; Spiperone; Tritium | 1993 |
Comparative study of 2-(4-ethyl-1-piperazinyl)-4-(fluorophenyl)-5,6,7,8,9, 10-hexahydrocycloocta[b]pyridine (AD-5423) and haloperidol for their pharmacological activities related to antipsychotic efficacy and/or adverse side-effects.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Body Temperature; Brain; Drug Synergism; Haloperidol; Male; Piperazines; Piperidines; Rats; Rats, Wistar; Receptors, Dopamine; Veratrine | 1993 |
Determination of a novel anti-psychotic agent AD-5423 and its metabolites in plasma by high-performance liquid chromatography with fluorescence detection.
Topics: Adult; Animals; Antipsychotic Agents; Calibration; Chromatography, High Pressure Liquid; Dogs; Haplorhini; Humans; Male; Oxidation-Reduction; Piperazines; Piperidines; Rats; Rats, Sprague-Dawley; Reference Standards; Reference Values; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence | 1997 |
Blonanserin. AD 5423.
Topics: Animals; Antipsychotic Agents; Clinical Trials as Topic; Drugs, Investigational; Humans; Piperazines; Piperidines | 1999 |
The effects of neuroleptics on the GABA-induced Cl- current in rat dorsal root ganglion neurons: differences between some neuroleptics.
Topics: Animals; Antipsychotic Agents; Cells, Cultured; Chloride Channel Agonists; Chloride Channels; Clozapine; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Synergism; gamma-Aminobutyric Acid; Ganglia, Spinal; Haloperidol; Incidence; Membrane Potentials; Piperazines; Piperidines; Quetiapine Fumarate; Rats; Rats, Wistar; Seizures | 2002 |
Crystal structure of an antipsychotic agent, 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine (blonanserin).
Topics: Antipsychotic Agents; Crystallography; Models, Molecular; Molecular Conformation; Molecular Structure; Piperazines; Piperidines | 2002 |
Blonanserin. AD 5423.
Topics: Animals; Antipsychotic Agents; Drug Tolerance; Humans; Mice; Piperazines; Piperidines; Psychotic Disorders | 2002 |
Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioral changes in mice.
Topics: Animals; Disease Models, Animal; Immobilization; Male; Mice; Motor Activity; Phencyclidine; Piperazines; Piperidines; Schizophrenia | 2003 |
Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423, a novel antipsychotic agent.
Topics: Antipsychotic Agents; Humans; Microsomes, Liver; Piperazines; Piperidines; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Stereoisomerism; Structure-Activity Relationship | 2005 |
Efficacy of blonanserin in combination therapy for treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Female; Humans; Piperazines; Piperidines; Treatment Outcome | 2009 |
Atypical antipsychotic properties of blonanserin, a novel dopamine D2 and 5-HT2A antagonist.
Topics: Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Haloperidol; Male; Mice; Mice, Inbred Strains; Nucleus Accumbens; Piperazines; Piperidines; Proto-Oncogene Proteins c-fos; Pyridines; Serotonin 5-HT2 Receptor Antagonists | 2010 |
Adjunctive treatment with low-dosage aripiprazole for blonanserin-induced hyperprolactinemia in a female patient with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dopamine Antagonists; Female; Humans; Hyperprolactinemia; Piperazines; Piperidines; Quinolones; Schizophrenia | 2010 |
Case of delirium complicated with pneumonia that improved with blonanserin administration.
Topics: Aged; Antipsychotic Agents; Delirium; Humans; Male; Piperazines; Piperidines; Pneumonia; Psychiatric Status Rating Scales; Psychomotor Agitation; Risperidone | 2010 |
Sensitive analysis of blonanserin, a novel antipsychotic agent, in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry.
Topics: Antipsychotic Agents; Chromatography, High Pressure Liquid; Humans; Mass Spectrometry; Piperazines; Piperidines; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Microextraction; Tandem Mass Spectrometry | 2010 |
Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex.
Topics: Animals; Antipsychotic Agents; Brain; Dopamine; Male; Microdialysis; Norepinephrine; Piperazines; Piperidines; Prefrontal Cortex; Protein Binding; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Receptors, Adrenergic, alpha-2; Receptors, Dopamine D2; Risperidone; Telemetry | 2011 |
Neuroleptic malignant syndrome induced by blonanserin.
Topics: Adult; Female; Humans; Neuroleptic Malignant Syndrome; Piperazines; Piperidines | 2011 |
Olfactory reference syndrome treated by blonanserin augmentation.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Drug Therapy, Combination; Humans; Male; Olfactory Perception; Piperazines; Piperidines; Schizophrenia, Paranoid; Syndrome | 2011 |
Blonanserin in the treatment of delirium.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Dopamine Antagonists; Female; Humans; Male; Middle Aged; Piperazines; Piperidines; Retrospective Studies; Serotonin Antagonists; Treatment Outcome | 2011 |
Three cases of schizophrenia showing improvement after switching to blonanserin.
Topics: Adult; Antipsychotic Agents; Delusions; Dopamine Antagonists; Hallucinations; Humans; Male; Piperazines; Piperidines; Schizophrenia; Serotonin Antagonists; Treatment Outcome | 2011 |
The relationship between the plasma concentration of blonanserin, and its plasma anti-serotonin 5-HT(2A) activity/anti-dopamine D₂ activity ratio and drug-induced extrapyramidal symptoms.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Aged; Piperazines; Piperidines; Receptors, Dopamine D2; Receptors, Serotonin, 5-HT2; Schizophrenia | 2012 |
Development and validation of a stability-indicating gas chromatographic method for quality control of residual solvents in blonanserin: a novel atypical antipsychotic agent.
Topics: 2-Propanol; Antipsychotic Agents; Chromatography, Gas; Drug Contamination; Drug Stability; Ethanol; Limit of Detection; Piperazines; Piperidines; Reproducibility of Results; Solvents; Toluene | 2012 |
Improvement in quetiapine-induced hypoglycemia following a switch to blonanserin.
Topics: Antipsychotic Agents; Dibenzothiazepines; Female; Humans; Hypoglycemia; Middle Aged; Piperazines; Piperidines; Quetiapine Fumarate | 2012 |
Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein.
Topics: Animals; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Brain; Cell Line, Transformed; Humans; Isoxazoles; LLC-PK1 Cells; Mice; Mice, Inbred Strains; Mice, Knockout; Paliperidone Palmitate; Piperazines; Piperidines; Pyrimidines; Risperidone; Swine | 2012 |
Quetiapine-induced insulin resistance after switching from blonanserin despite a loss in both bodyweight and waist circumference.
Topics: Antipsychotic Agents; Dibenzothiazepines; Female; Homeostasis; Humans; Insulin Resistance; Piperazines; Piperidines; Quetiapine Fumarate; Schizophrenia; Waist Circumference; Weight Loss; Young Adult | 2012 |
Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.
Topics: Adult; Antipsychotic Agents; Blood-Brain Barrier; Brain; Case-Control Studies; Corpus Striatum; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Piperazines; Piperidines; Positron-Emission Tomography; Pyrrolidines; Raclopride; Receptors, Dopamine D2; Salicylamides; Schizophrenia; Tissue Distribution; Young Adult | 2013 |
Blonanserin for the treatment of delirium patients at an emergency medical care center: an open-label study.
Topics: Aged; Critical Care; Delirium; Emergency Treatment; Female; Humans; Male; Pilot Projects; Piperazines; Piperidines; Treatment Outcome | 2013 |
Blonanserin reverses the phencyclidine (PCP)-induced impairment in novel object recognition (NOR) in rats: role of indirect 5-HT(1A) partial agonism.
Topics: Animals; Female; Isoindoles; Phencyclidine; Piperazines; Piperidines; Pyridines; Pyrimidines; Rats; Rats, Long-Evans; Receptor, Serotonin, 5-HT1A; Recognition, Psychology; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists | 2013 |
Effect of blonanserin on methamphetamine-induced disruption of latent inhibition and c-Fos expression in rats.
Topics: Amygdala; Animals; Antipsychotic Agents; Conditioning, Classical; Dopamine Antagonists; Dopamine Uptake Inhibitors; Male; Methamphetamine; Nucleus Accumbens; Piperazines; Piperidines; Prefrontal Cortex; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley | 2013 |
Successful treatment with blonanserin for drug-induced hyperprolactinemia in chronic schizophrenia patients: a six-month follow-up of two cases.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Female; Follow-Up Studies; Humans; Hyperprolactinemia; Male; Middle Aged; Piperazines; Piperidines; Prolactin; Schizophrenia | 2013 |
Simultaneous determination of blonanserin and its four metabolites in human plasma using ultra-performance liquid chromatography-tandem mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Humans; Least-Squares Analysis; Piperazines; Piperidines; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Tandem Mass Spectrometry | 2013 |
Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Brain; Cerebral Cortex; Dopamine; Glutamic Acid; Hippocampus; Isoindoles; Lurasidone Hydrochloride; Male; Microdialysis; Neurotransmitter Agents; Nucleus Accumbens; Piperazines; Piperidines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Synaptic Transmission; Thiazoles | 2014 |
Delusional infestation responding to blonanserin.
Topics: Antipsychotic Agents; Delusional Parasitosis; Humans; Male; Middle Aged; Piperazines; Piperidines | 2013 |
The pharmacokinetic and safety profiles of blonanserin in healthy Chinese volunteers after single fasting doses and single and multiple postprandial doses.
Topics: Administration, Oral; Adult; Asian People; Cohort Studies; Dose-Response Relationship, Drug; Fasting; Fatigue; Follow-Up Studies; Food-Drug Interactions; Humans; Male; Piperazines; Piperidines; Postprandial Period; Young Adult | 2014 |
Comprehensive DNA methylation analysis of human neuroblastoma cells treated with blonanserin.
Topics: Antipsychotic Agents; Cell Line, Tumor; CpG Islands; DNA Methylation; Dose-Response Relationship, Drug; Genome, Human; Humans; Neuroblastoma; Piperazines; Piperidines | 2014 |
Blonanserin improved dystonia induced by risperidone or olanzapine in two patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dystonia; Female; Humans; Olanzapine; Piperazines; Piperidines; Risperidone; Schizophrenia; Young Adult | 2014 |
Long-term efficacy and safety of blonanserin in patients with first-episode schizophrenia: a 1-year open-label trial.
Topics: Adult; Antipsychotic Agents; Female; Follow-Up Studies; Humans; Male; Piperazines; Piperidines; Quality of Life; Schizophrenia; Time Factors; Treatment Outcome | 2014 |
Evaluation of human D-amino acid oxidase inhibition by anti-psychotic drugs in vitro.
Topics: Antipsychotic Agents; D-Amino-Acid Oxidase; Enzyme Activation; Humans; Piperazines; Piperidines; Risperidone | 2014 |
A case report of blonanserin-induced hyponatremia.
Topics: Antidepressive Agents; Depressive Disorder, Major; Female; Humans; Hyponatremia; Middle Aged; Piperazines; Piperidines; Psychotic Disorders | 2014 |
Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits: the complex mechanism of blonanserin action involving D₃-5-HT₂A and D₁-NMDA receptors in the mPFC.
Topics: Amphetamines; Animals; Benzazepines; Benzodiazepines; Dopamine; Dopamine Agonists; Isoquinolines; Male; Mice; Olanzapine; Phencyclidine; Phosphorylation; Piperazines; Piperidines; Prefrontal Cortex; Protein Kinase Inhibitors; Receptors, Dopamine D1; Receptors, Dopamine D3; Receptors, N-Methyl-D-Aspartate; Recognition, Psychology; Serotonin Receptor Agonists; Sulfonamides; Tetrahydronaphthalenes | 2015 |
The position of blonanserin as a treatment for schizophrenia.
Topics: Antipsychotic Agents; Double-Blind Method; Humans; Multicenter Studies as Topic; Piperazines; Piperidines; Randomized Controlled Trials as Topic; Schizophrenia | 2014 |
Blonanserin ameliorated the tendency toward QTc prolongation associated with risperidone in a patient with schizophrenia.
Topics: Adult; Antipsychotic Agents; Female; Humans; Long QT Syndrome; Piperazines; Piperidines; Risperidone; Schizophrenia | 2015 |
The serotonin 5-HT₁A receptor agonist tandospirone improves executive function in common marmosets.
Topics: Animals; Antipsychotic Agents; Callithrix; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Executive Function; Haloperidol; Isoindoles; Male; Piperazines; Piperidines; Psychological Tests; Psychotropic Drugs; Pyrimidines; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D1; Risperidone; Serotonin 5-HT1 Receptor Agonists | 2015 |
Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range.
Topics: Animals; Antipsychotic Agents; Cells, Cultured; Cricetinae; Cricetulus; Disease Models, Animal; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Hyperkinesis; Male; Piperazines; Piperidines; Protein Binding; Rats, Sprague-Dawley; Receptors, Dopamine D3; Serotonin 5-HT2 Receptor Antagonists | 2015 |
Atypical antipsychotic properties of AD-6048, a primary metabolite of blonanserin.
Topics: Animals; Antipsychotic Agents; Apomorphine; Basal Ganglia Diseases; Behavior, Animal; Catalepsy; Corpus Striatum; Dose-Response Relationship, Drug; Gene Expression; Haloperidol; Injections, Subcutaneous; Male; Mice; Nucleus Accumbens; Oncogene Proteins v-fos; Piperazines; Piperidines; Pyridines | 2015 |
Dopamine D3 receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement.
Topics: Acetylcholine; Animals; Benzopyrans; Brain Chemistry; Cerebral Cortex; Dopamine; Dopamine Antagonists; Excitatory Amino Acid Antagonists; Fluorenes; Haloperidol; Male; Mice; Mice, Inbred C57BL; Nootropic Agents; Oxazines; Phencyclidine; Piperazines; Piperidines; Rats, Long-Evans; Receptors, Dopamine D3 | 2015 |
The atypical antipsychotic blonanserin reverses (+)-PD-128907- and ketamine-induced deficit in executive function in common marmosets.
Topics: Animals; Antipsychotic Agents; Benzopyrans; Callithrix; Cognition Disorders; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Executive Function; Female; Ketamine; Male; Mental Recall; Oxazines; Piperazines; Piperidines | 2016 |
Effectiveness of blonanserin for patients with drug treatment-resistant schizophrenia and dopamine supersensitivity: A retrospective analysis.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Dopamine; Drug Resistance; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Piperidines; Psychiatric Status Rating Scales; Retrospective Studies; Schizophrenia | 2016 |
Effects of clozapine on adipokine secretions/productions and lipid droplets in 3T3-L1 adipocytes.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Animals; Antipsychotic Agents; Cell Survival; Clozapine; Leptin; Lipid Droplets; Mice; Piperazines; Piperidines | 2017 |
Effects of food and grapefruit juice on single-dose pharmacokinetics of blonanserin in healthy Chinese subjects.
Topics: Adult; Area Under Curve; Biological Availability; Citrus paradisi; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Food-Drug Interactions; Fruit and Vegetable Juices; Healthy Volunteers; Humans; Intestines; Male; Piperazines; Piperidines; Young Adult | 2018 |
Olanzapine, blonanserin, and aripiprazole associated with different frontostriatal reward system activation in patients with schizophrenia.
Topics: Adult; Anticipation, Psychological; Antipsychotic Agents; Aripiprazole; Female; Humans; Magnetic Resonance Imaging; Male; Olanzapine; Piperazines; Piperidines; Prefrontal Cortex; Reward; Schizophrenia; Ventral Striatum | 2018 |
Comparison of Dopamine D3 and D2 Receptor Occupancies by a Single Dose of Blonanserin in Healthy Subjects: A Positron Emission Tomography Study With [11C]-(+)-PHNO.
Topics: Adult; Antipsychotic Agents; Brain; Dopamine Agents; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Oxazines; Piperazines; Piperidines; Positron-Emission Tomography; Protein Binding; Radiopharmaceuticals; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2018 |
Montmorillonite and Laponite Clay Materials for the Solidification of Lipid-Based Formulations for the Basic Drug Blonanserin: In Vitro and in Vivo Investigations.
Topics: Bentonite; Chromatography, High Pressure Liquid; Drug Carriers; Drug Compounding; Drug Delivery Systems; Lipids; Microscopy, Electron, Scanning; Piperazines; Piperidines; Silicates; X-Ray Diffraction | 2018 |
Antidepressant activities of escitalopram and blonanserin on prenatal and adolescent combined stress-induced depression model: Possible role of neurotrophic mechanism change in serum and nucleus accumbens.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Citalopram; Corticosterone; Depression; Disease Models, Animal; Female; Hippocampus; Male; Nucleus Accumbens; Piperazines; Piperidines; Pregnancy; Rats; Social Behavior; Swimming | 2019 |
Combination treatment with guanfacine extended release and blonanserin for Tourette's syndrome comorbid with attention deficit hyperactivity disorder.
Topics: Adrenergic alpha-2 Receptor Agonists; Attention Deficit Disorder with Hyperactivity; Child; Comorbidity; Delayed-Action Preparations; Drug Therapy, Combination; Guanfacine; Humans; Male; Piperazines; Piperidines; Tourette Syndrome | 2019 |
Experimental analysis of the onset mechanism of TdP reported in an LQT3 patient during pharmacological treatment with serotonin-dopamine antagonists against insomnia and nocturnal delirium.
Topics: Action Potentials; Anesthetics, Inhalation; Animals; Calcium Channel Agonists; Cardiac Conduction System Disease; Delirium; Dogs; Dopamine Antagonists; Dose-Response Relationship, Drug; Electrocardiography; Female; Halothane; Heart Conduction System; Humans; Isoindoles; Long QT Syndrome; Middle Aged; Models, Animal; Piperazines; Piperidines; Potassium Channel Blockers; Serotonin Antagonists; Sleep Initiation and Maintenance Disorders; Thiazoles; Torsades de Pointes | 2020 |
Blonanserin patch for schizophrenia.
Topics: Humans; Piperazines; Piperidines; Schizophrenia | 2020 |
Blonanserin suppresses impulsive action in rats.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Impulsive Behavior; Male; Mental Disorders; Piperazines; Piperidines; Rats; Rats, Wistar; Reaction Time | 2019 |
Chronic treatment with the antipsychotic drug blonanserin modulates the responsiveness to acute stress with anatomical selectivity.
Topics: Animals; Antipsychotic Agents; Brain; Drug Administration Schedule; Genes, Immediate-Early; Male; Piperazines; Piperidines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Schizophrenia; Stress, Psychological | 2020 |
The Influence of Solidification on the in vitro Solubilisation of Blonanserin Loaded Supersaturated Lipid-Based Oral Formulations.
Topics: Administration, Oral; Biological Availability; Drug Carriers; Drug Delivery Systems; Emulsions; Lipids; Piperazines; Piperidines; Solubility | 2021 |
Behavioral and molecular effects of the antipsychotic drug blonanserin in the chronic mild stress model.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Brain; Cytoskeletal Proteins; Disease Models, Animal; Male; Maze Learning; Nerve Tissue Proteins; Oxidoreductases; Piperazines; Piperidines; Rats, Wistar; Stress, Psychological | 2021 |
COVID-19 infection in Hokkaido, Japan might depend on the viscosity of atmospheric air.
Topics: COVID-19; Double-Blind Method; Humans; Japan; Piperazines; Piperidines; SARS-CoV-2; Schizophrenia; Transdermal Patch; Viscosity | 2021 |
Switching from blonanserin tablets to blonanserin transdermal patches improves tardive dyskinesia: A case report.
Topics: Antipsychotic Agents; Humans; Piperazines; Piperidines; Tablets; Tardive Dyskinesia; Transdermal Patch | 2021 |
The type rather than the daily dose or number of antipsychotics affects the incidence of hyperglycemic progression.
Topics: Adult; Antipsychotic Agents; Clozapine; Dibenzothiepins; Female; Haloperidol; Humans; Hyperglycemia; Incidence; Japan; Male; Middle Aged; Piperazines; Piperidines; Prospective Studies; Schizophrenia | 2022 |
Improved response to electroconvulsive therapy after switching from haloperidol to blonanserin in a patient with treatment-resistant schizophrenia.
Topics: Antipsychotic Agents; Electroconvulsive Therapy; Haloperidol; Humans; Piperazines; Piperidines; Schizophrenia; Schizophrenia, Treatment-Resistant | 2022 |
Case report of bradycardia induced by blonanserin in schizophrenia.
Topics: Antipsychotic Agents; Bradycardia; Humans; Piperazines; Piperidines; Schizophrenia | 2022 |
Early improvement as a predictor of response to blonanserin transdermal patch in patients with schizophrenia.
Topics: Antipsychotic Agents; Humans; Piperazines; Piperidines; Schizophrenia; Transdermal Patch | 2022 |
Effect of Blonanserin on the Proliferation and Migration of Glioblastoma Cells.
Topics: Antipsychotic Agents; Cell Proliferation; Glioblastoma; Humans; Piperidines | 2023 |